FDA to decide on Intellia's one-time HAE gene editor by March 2027

Intellia Therapeutics has a regulatory decision date for its first potential commercial product. The US Food and Drug Administration will rule on lonvo-z, a one-time CRISPR-based treatment for hereditary angioedema (HAE), by 10 March 2027. The company disclosed this on 5 November alongside its third-quarter 2026 results.

The agency accepted the biologics licence application and granted it priority review, a status given to candidates that could materially improve care for serious conditions. As general context, priority review usually means a shorter review than the standard route. Lonvo-z is delivered in vivo, meaning the gene editing takes place inside the patient's body.

Intellia also said it has finished enrolling MAGNITUDE-2, a Phase 3 study of nex-z in hereditary transthyretin amyloidosis with polyneuropathy. That makes it the second late-stage programme with a completed enrolment milestone to report, though the update gave no timing for data.

On the balance sheet, Intellia reported cash of $614.8 million and said it has arranged a term loan of up to $400 million with OrbiMed. The material available did not set out the loan's terms, such as its pricing, tranches or conditions, so how much of the facility is accessible, and when, is unclear.